AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

Cardiff Oncology’s stock price jumped 50% following the Phase II data. Credit: aslysun / Shutterstock. US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial ...

Patients saw an average 14.5% relative improvement in disease-free survival when compared with the placebo arm of the study after 54 months. Credit: shutterstock / Peakstock Candel Therapeutics’s ...

A clinical benefit rate of 62.5% was noted among subjects with both mutant and wild-type oestrogen receptor alpha gene disease. Credit: Andrei_R/Shutterstock. Arvinas and Pfizer have shared ...

The UK is seeing an overall improvement in its desirability as a clinical trials location, but it still has ground to make up.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.